BR112013027150A2 - thera - Google Patents

thera

Info

Publication number
BR112013027150A2
BR112013027150A2 BR112013027150A BR112013027150A BR112013027150A2 BR 112013027150 A2 BR112013027150 A2 BR 112013027150A2 BR 112013027150 A BR112013027150 A BR 112013027150A BR 112013027150 A BR112013027150 A BR 112013027150A BR 112013027150 A2 BR112013027150 A2 BR 112013027150A2
Authority
BR
Brazil
Prior art keywords
grf
growth hormone
analogues
leucine
releasing factor
Prior art date
Application number
BR112013027150A
Other languages
English (en)
Portuguese (pt)
Inventor
Habi Abdelkrim
G Peri Krishna
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of BR112013027150A2 publication Critical patent/BR112013027150A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112013027150A 2011-04-21 2012-04-17 thera BR112013027150A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477775P 2011-04-21 2011-04-21
PCT/CA2012/050242 WO2012142706A1 (en) 2011-04-21 2012-04-17 Growth hormone releasing factor (grf) analogs and uses thereof

Publications (1)

Publication Number Publication Date
BR112013027150A2 true BR112013027150A2 (pt) 2017-06-06

Family

ID=47021786

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013027150A BR112013027150A2 (pt) 2011-04-21 2012-04-17 thera

Country Status (10)

Country Link
US (1) US8361964B2 (enExample)
EP (1) EP2699591A4 (enExample)
JP (1) JP6113144B2 (enExample)
KR (1) KR20140027284A (enExample)
CN (1) CN103547591A (enExample)
AR (1) AR087727A1 (enExample)
BR (1) BR112013027150A2 (enExample)
CA (1) CA2833434A1 (enExample)
MX (1) MX2013012259A (enExample)
WO (1) WO2012142706A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9988428B2 (en) 2016-04-19 2018-06-05 Griffon Pharmaceuticals Inc. Pegylated bioactive peptides and uses thereof
KR20230035600A (ko) * 2020-07-05 2023-03-14 쎄러테크놀로지스 인코포레이티드 Ghrh 유사체의 저-용량 약제학적 조성물 및 이들의 용도

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518586A (en) 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US4617149A (en) 1983-09-21 1986-10-14 Eli Lilly And Company Growth hormone release factor analogs
US4622312A (en) 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4801456A (en) 1987-07-09 1989-01-31 International Minerals & Chemical Corp. Growth hormone-releasing factor analogs
ES2054754T3 (es) * 1987-09-18 1994-08-16 Hoffmann La Roche Analogos ciclicos del grf.
CA2040649A1 (en) * 1990-04-24 1991-10-25 Gerald S. Brooke Growth hormone releasing factor analogs
CA2084061A1 (en) 1991-04-09 1992-10-10 Arthur M. Felix Growth hormone releasing factor analogs
US5262519A (en) * 1991-05-15 1993-11-16 The Salk Institute For Biological Studies GRF analogs XI
EP0820296A4 (en) 1995-04-14 1999-06-30 Univ Tulane ANALOGS OF THE GROWTH HORMONE-RELEASING FACTOR
KR100543190B1 (ko) 1995-05-26 2006-06-23 떼라떼끄놀로지 인코퍼레이티드 향상된생물학적효능을갖는키메라성지방체-프로-지알에프유사체
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6057422A (en) 1998-11-25 2000-05-02 The Administrators Of The Tulane Educational Fund Antagonistic analogs of GH-RH inhibiting IGF-I and -II
CA2422707A1 (en) 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
BR0206919A (pt) * 2001-02-02 2004-07-06 Conjuchem Inc Derivados de fator de liberação de hormÈnio de crescimento de longa duração
CN101481405A (zh) * 2001-06-08 2009-07-15 研究及应用科学协会股份有限公司 生长激素释放抑制因子-多巴胺嵌合类似物
NZ539218A (en) 2002-09-18 2008-03-28 Univ Montreal Ct Hospitalier Chum Synthetic GHRH analogues of 29 amino acids or more
WO2004105789A1 (en) 2003-05-29 2004-12-09 Theratechnologies Inc. Grf analog compositions and their use
WO2006042408A1 (en) 2004-10-20 2006-04-27 Theratechnologies Inc. Gh secretagogues and uses thereof
TW200517400A (en) 2003-08-05 2005-06-01 Univ Tulane Antagonistic analogs of GH-RH (2003)
AU2004281084B2 (en) 2003-10-20 2010-08-12 Theratechnologies Inc. Use of growth hormone releasing factor analogs in treating patients suffering from wasting
US8021859B2 (en) 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
WO2009009727A2 (en) 2007-07-12 2009-01-15 Akela Pharma Srl Ghrh analogs and therapeutic uses thereof
US20110021429A1 (en) 2007-10-01 2011-01-27 Pierrette Gaudreau Renoprotection by growth hormone-releasing hormone and agonists
EP2421548A4 (en) 2009-04-20 2012-09-26 Theratechnologies Inc USE OF (HEXENOYL TRANS-3) HGRF (1-44) NH2 AND SIMVASTATIN IN COMBINED TREATMENT

Also Published As

Publication number Publication date
JP6113144B2 (ja) 2017-04-12
WO2012142706A1 (en) 2012-10-26
CN103547591A (zh) 2014-01-29
AR087727A1 (es) 2014-04-16
JP2014515751A (ja) 2014-07-03
EP2699591A4 (en) 2014-05-07
CA2833434A1 (en) 2012-10-26
KR20140027284A (ko) 2014-03-06
MX2013012259A (es) 2013-11-22
EP2699591A1 (en) 2014-02-26
US20120270784A1 (en) 2012-10-25
US8361964B2 (en) 2013-01-29

Similar Documents

Publication Publication Date Title
BR112016016290A2 (pt) Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
PH12014502778A1 (en) Antibody formulation
CL2014003421A1 (es) Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad.
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
BR112014026057A2 (pt) análogos limitados por anel como inibidores de arginase
CL2013002933A1 (es) Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; polipeptido; uso de la composicion inmunogenica que sirve para tratar afecciones de infeccion por prv en un animal
CL2015001256A1 (es) Compuestos derivados del acido indaniloxi-dihidro-benzofuranil-acetico, agonistas del receptor acoplado a proteinas g40 (gpr40); sal; composicion farmaceutica; y uso para profilaxis y/o terapia de enfermedades metabolicas tales como diabetes y sus afecciones asociadas tales como resistencia a la insulina y obesidad, entre otras.
PE20151727A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
IL216466B (en) Compositions for respiratory delivery of active agents and associated methods and systems
CL2012000026A1 (es) Formulación farmacéutica acuosa que contiene una insulina, un análogo de insulina o un derivado insulínico, o una de sus sales farmacológicamente tolerables, y metionina; proceso para preparar dicha formulación; medicamento que la contiene; y su uso para tratar la diabetes mellitus.
BR112014018475A8 (pt) Compostos de imidazopirrolidinona, suas formas cristalinas e seu uso, e composição farmacêutica
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
CL2015001652A1 (es) Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor.
BR112013014616A2 (pt) sistema terapêutico transdérmico para a administração de uma substância ativa
CL2014000289A1 (es) Compuestos derivados de 3,4-dihidro-1h-[1,8]naftiridonas sustituidas, inhibidores de la actividad de la enzima fabl; proceso para preparar dichos compuestos; composicion farmaceutica que los comprende; y proceso para preparar esta composicion farmaceutica.
CL2013002129A1 (es) Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras.
CR20150360A (es) Sistema de liberación transdérmica
BR112014021497A2 (pt) sistema de entrega de fármaco baseado em jcv-vlp
BR112013027150A2 (pt) thera
AR118842A2 (es) Composición farmacéutica que contiene tamoxifen y endoxifen y procedimiento para prepararla

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2510 DE 12/02/2019.